A Study to Assess Adverse Events and Change in Disease State in Adult Participants Being Treated With Humira in Participants Diagnosed With Pyoderma Gangrenosum (PG)
Launched by ABBVIE · Feb 10, 2021
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the safety and effects of Humira, a medication used to treat Pyoderma Gangrenosum (PG), which is a serious skin condition that causes painful sores. The goal of the study is to understand how often participants experience infections as side effects while using Humira. This is important because PG can be challenging to diagnose and treat, and Humira is currently the only approved treatment for this condition in Japan.
To be eligible for the study, participants must be adults who have been diagnosed with PG and have started treatment with Humira within the last two weeks. Participants will be monitored closely during regular visits to their doctor, where they will be checked for any side effects and have their treatment progress assessed through interviews. It's important to note that this study may require more visits and monitoring than typical treatment, but it aims to provide valuable information on the use of Humira for PG.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diagnosed with Pyoderma Gangrenosum (PG).
- • Have been prescribed Humira for PG treatment within 14 days.
- Exclusion Criteria:
- • - Have Pyoderma Gangrenosum (PG) in previous treatment with Humira.
About Abbvie
AbbVie is a global biopharmaceutical company dedicated to developing innovative therapies that address complex health challenges. Founded in 2013 as a spin-off from Abbott Laboratories, AbbVie focuses on key therapeutic areas, including immunology, oncology, neuroscience, and virology. The company is committed to advancing scientific research and delivering groundbreaking treatments that enhance patient outcomes and quality of life. With a robust pipeline and a strong emphasis on collaboration, AbbVie strives to transform the future of medicine through its commitment to clinical excellence and patient-centered approaches.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Nagoya Shi, Aichi, Japan
Nagoya Shi, Aichi, Japan
Akita Shi, Akita, Japan
Fukuoka Shi, Fukuoka, Japan
Fukuoka Shi, Fukuoka, Japan
Kurume Shi, Fukuoka, Japan
Minokamo Shi, Gifu, Japan
Maebashi Shi, Gunma, Japan
Sapporo Shi, Hokkaido, Japan
Amagasaki Shi, Hyogo, Japan
Kobe Shi, Hyogo, Japan
Kobe Shi, Hyogo, Japan
Kanazawa Shi, Ishikawa, Japan
Kanazawa Shi, Ishikawa, Japan
Takamatsu Shi, Kagawa, Japan
Kawasaki City, Kanagawa, Japan
Yokohama Shi, Kanagawa, Japan
Kumamoto Shi, Kumamoto, Japan
Tsu Shi, Mie, Japan
Sendai Shi, Miyagi, Japan
Miyazaki Shi, Miyazaki, Japan
Matsumoto Shi, Nagano, Japan
Kashihara Shi, Nara, Japan
Okayama Shi, Okayama, Japan
Naha Shi, Okinawa, Japan
那覇市, Okinawa, Japan
Hirakata Shi, Osaka, Japan
Osaka Shi, Osaka, Japan
Koshigaya Shi, Saitama, Japan
Hamamatsu Shi, Shizuoka, Japan
Kakegawa Shi, Shizuoka, Japan
Shizuoka Shi, Shizuoka, Japan
Itabashi Ku, Tokyo, Japan
Shinjuku Ku, Tokyo, Japan
Yamanashi City, Yamanashi, Japan
Fukuchiyama Shi, , Japan
Osaka, , Japan
Takamatsu Shi, Kagawa, Japan
Bunkyo Ku, Tokyo, Japan
Sapporo Shi, , Japan
Sendai Shi, Miyagi, Japan
Nakagami Gun, Okinawa, Japan
Minato Ku, Tokyo, Japan
Sapporo Shi, Hokkaido, Japan
Osakasayama Shi, Osaka, Japan
Kobe, Hyogo, Japan
Kawasaki, Kanagawa, Japan
Yokohama Shi, Kanagawa, Japan
Naha, Okinawa, Japan
Koshigaya, Saitama, Japan
Okayama, , Japan
Tokyo, , Japan
Patients applied
Trial Officials
ABBVIE INC.
Study Director
AbbVie
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials